Previous 10 | Next 10 |
home / stock / gikly / gikly news
This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...
SAN CLEMENTE, Calif., Aug. 10, 2020 /PRNewswire/ -- ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in ...
SOUTH SAN FRANCISCO, Calif. , July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe , has launched TAVLESSE ® in Germany and the United Kingdom . It was approved by the European Co...
REDMOND, Wash. and NEW YORK , May 26, 2020 /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups ...
This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Soros Fund Management Holdings ar...
BARCELONA, Spain , May 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that it has received FDA approval for the Pr...
BARCELONA, Spain , April 28, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a treatment for rabies postexposure prop...
BARCELONA, Spain , April 20, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun iden...
BARCELONA, Spain , April 6, 2020 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 6, 2020 . Grifols' Annual Report on...
BARCELONA, Spain , Feb. 13, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced that its PharmacyKeeper Verif...
News, Short Squeeze, Breakout and More Instantly...
Grifols SA Barcelona ADR Company Name:
GIKLY Stock Symbol:
OTCMKTS Market:
Grifols SA Barcelona ADR Website:
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...